Publications

Greenland NY, Cowan JE, Ding CC, Sirohi D, Cooperberg MR, Carroll PR, Simko JP, Stohr BA, Zhang L, Chan E. Correlation of unfavourable and favourable histology at radical prostatectomy with Decipher scores and freedom from biochemical recurrence. Histopathology. 2025. PMID: 41171098


Li Zhang, PhD

Frazer K, Vijayaraghavan M. Syndemic lives of women who smoke and experience homelessness: secondary analysis of US qualitative data. Health promotion international. 2025. PMID: 41433202


Maya Vijayaraghavan, MD, MAS

Hines MR, Knight TE, McNerney KO, Leick MB, Jain T, Ahmed S, Frigault MJ, Hill JA, Jain MD, Johnson WT, Lin Y, Mahadeo KM, Maron GM, Marsh RA, Neelapu SS, Nikiforow S, Ombrello AK, Shah NN, Talleur AC, Turicek D, Vatsayan A, Wong SW, Maus MV, Komanduri KV, Berliner N, Henter JI, Perales MA, Frey NV, Teachey DT, Frank MJ, Shah NN. Erratum to <Immune Effector Cell-Associated Hemophagocytic Lymphohistiocytosis-Like Syndrome><[Transplant Cell Ther. 2023 Jul;29(7):438.e1-438.e16. Epub 2023 Mar 9]>. Transplantation and cellular therapy. 2025. PMID: 41067707


Krishna Komanduri, MD

Fergus KB, Newberg J, Greenstein R, Fejerman L, Carvajal-Carmona L, Collisson E, Dixit N, Frampton G, Huang FW, Neuhausen SL, Ziv E. Association between ancestry and tumor somatic mutations in a large national cohort of women with breast cancer. NPJ breast cancer. 2025. PMID: 41162424


Franklin Huang, MD, PhD

Lai TYY, Arias L, Cheung CMG, Couturier A, Liu W, O'Leary OE, Rafijah N, Shah N, Yoon YH, Patel S, POYANG Study investigators. POYANG: A phase III randomized clinical trial of faricimab for choroidal neovascularization secondary to pathologic myopia: study design and rationale. Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie. 2025. PMID: 41152620


Neil Pravin Shah, MD, PhD

Wang H, Ge Y, Shao W, Xiong X, Li G, Li N, Hu X, Chen G, Dong K, Ai W, Yu Z, Zheng Z, Wang C, Yao F, Cao X, Li S, Zhao J, Ke W, Tao C, Hou Y, Petrozza A, Fang G. Yttrium oxide engineered substrate enables improved durability for perovskite solar cells. Nature communications. 2025. PMID: 41152230


Weiyun Ai, MD, PhD

Krasnow NA, Jayaraj M, Salans M, Kuwahara K, Zhou MH, Fisch S, Boreta L, Braunstein SE, Aghi MK, Batra-Sharma H, Majure M, Chien J, Rugo HS, Morshed RA, Vasudevan HN, Melisko ME, Huppert LA. Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study. Breast cancer research : BCR. 2025. PMID: 41153023


Melanie Majure, MD

Krasnow NA, Jayaraj M, Salans M, Kuwahara K, Zhou MH, Fisch S, Boreta L, Braunstein SE, Aghi MK, Batra-Sharma H, Majure M, Chien J, Rugo HS, Morshed RA, Vasudevan HN, Melisko ME, Huppert LA. Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study. Breast cancer research : BCR. 2025. PMID: 41153023


Hope Rugo, MD

Krasnow NA, Jayaraj M, Salans M, Kuwahara K, Zhou MH, Fisch S, Boreta L, Braunstein SE, Aghi MK, Batra-Sharma H, Majure M, Chien J, Rugo HS, Morshed RA, Vasudevan HN, Melisko ME, Huppert LA. Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study. Breast cancer research : BCR. 2025. PMID: 41153023


Jo Chien, MD

Krasnow NA, Jayaraj M, Salans M, Kuwahara K, Zhou MH, Fisch S, Boreta L, Braunstein SE, Aghi MK, Batra-Sharma H, Majure M, Chien J, Rugo HS, Morshed RA, Vasudevan HN, Melisko ME, Huppert LA. Evaluating survival trends over time in patients with metastatic breast cancer and brain metastases: a single center retrospective cohort study. Breast cancer research : BCR. 2025. PMID: 41153023


Michelle Melisko, MD

Jindal T, Jiang CY, Alhalabi O, Davidsohn M, Freeman D, Epstein IY, Bakaloudi DR, Talukder R, Nizam A, Nguyen CB, Oh E, Tsung I, Glover MJ, Khaki AR, Taylor AK, Jaime-Casas S, Jang A, Lemke E, Pywell C, Evans ST, Shin D, Bilen MA, Basu A, Kilari D, Tripathi A, Brown J, Emamekhoo H, Davis NB, Shah S, Gupta S, Grivas P, Bellmunt J, Alva A, Campbell MT, Koshkin VS. Efficacy of sacituzumab govitecan after enfortumab vedotin in advanced urothelial carcinoma: Analysis of the UNITE study. Urologic oncology. 2025. PMID: 41152111


Vadim Koshkin, MD

Reig M, Sanduzzi-Zamparelli M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M, Garcia-Criado Á, Díaz A, Llarch N, Iserte G, Mollà M, Kelley RK, Galle PR, Mazzaferro V, Salem R, Sangro B, Singal AG, Vogel A, Yanagihara TK, Ayuso C, Torres F, Bruix J. BCLC strategy for prognosis prediction and treatment recommendations: The 2026 update. Journal of hepatology. 2025. PMID: 41151697


Robin Kate ("Katie") Kelley, MD

Smith CC, Zwerner IM, Gudjonsson JE, Ward NL. Reevaluating the Imiquimod Model: A Barrier to Translational Progress in Psoriasis. The Journal of investigative dermatology. 2025. PMID: 41143763


Catherine Smith, MD

DeBoer RJ, Uwamahoro P, Ndoli DA, Rugengamanzi E, Mulindabigwi A, Bigirimana JB, Musafiri T, Slater SE, Van Loon K, Sudore RL, Anderson WG, Sanders JJ, Cubaka VK. Adaptation of a serious illness communication training intervention for the Rwandan context. Journal of pain and symptom management. 2025. PMID: 41135916


Katherine Van Loon, MD, MPH

DeBoer RJ, Uwamahoro P, Ndoli DA, Rugengamanzi E, Mulindabigwi A, Bigirimana JB, Musafiri T, Slater SE, Van Loon K, Sudore RL, Anderson WG, Sanders JJ, Cubaka VK. Adaptation of a serious illness communication training intervention for the Rwandan context. Journal of pain and symptom management. 2025. PMID: 41135916


Rebecca Deboer, MD, MA

Goudy L, Ha A, Borah AA, Umhoefer JM, Chow L, Tran C, Winters A, Talbot A, Hernandez R, Li Z, Subramanya S, Arab A, Kale N, Lee JHJ, Muldoon JJ, Liu C, Schmidt R, Santangelo P, Carnevale J, Eyquem J, Shy BR, Marson A, Gilbert LA. Integrated epigenetic and genetic programming of primary human T cells. Nature biotechnology. 2025. PMID: 41120666


Julia Carnevale, MD

Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy. 2025. PMID: 41104991


Alfred Chung, MD

Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy. 2025. PMID: 41104991


Ajai Chari, MD

Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy. 2025. PMID: 41104991


Darren Pan, MD

Suresh A, Pan D, Lipof J, Kumar A, Arora S, Sayre P, Wolf J, Martin T, Chari A, Chung A. How should we choose optimal salvage treatments following BCMA-directed CAR T-cell therapy? Immunotherapy. 2025. PMID: 41104991


Jodi Lipof, MD